Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences, Inc. (PCRX) is a healthcare company (drug manufacturers - specialty & generic) based in the United States. The share price is $36.48, up 0.00% on the day, which values the company at $1.46B. Price as of 18 Nov 2026, 12:06 UTC, from Yahoo Finance.

Key facts

Share price
$36.48+0.00% today
Market value
$1.46B
P/E ratio
39.2×last 12 months
Forward P/E
10.2×
Funk Score
53/100
Against its own history
Well below its usual priceusual price $83.46
200-week average
$27.3333% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Pacira BioSciences, Inc. in more detail

PCRX trades at 39.2× its last twelve months' earnings, 10.2× next year's expected earnings, 2.0× sales. Measured against its own history, the price is 56% below what its usual multiples would imply ($83.46) — well below its usual price. It sits 33% above its 200-week average of $27.33.

Over the last five fiscal years Pacira BioSciences, Inc. has compounded revenue 11.1% a year, earnings per share -45.5% a year, free cash flow 28.4% a year. Its Funk Score is 53 out of 100 (financial strength 3.9, profitability 2.9, growth 5.7, value 8.8, each out of 10).

In its favour: Strong Piotroski score; Five straight years of revenue growth. Worth checking: Thin interest cover; Low return on invested capital.

Pacira BioSciences, Inc. (PCRX): questions and answers

What is PCRX's P/E ratio?

Pacira BioSciences, Inc. trades at 39.2× its last twelve months' earnings and 10.2× next year's expected earnings. At its fiscal year-ends over the past 5 years the P/E ranged from 18.0× to 161.7×, with a median of 65.4×.

What is PCRX's PEG ratio?

Pacira BioSciences, Inc.'s PEG ratio is 0.99 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Pacira BioSciences, Inc.'s market cap?

Pacira BioSciences, Inc. is valued at $1.46B at a share price of $36.48.

Is PCRX overvalued or undervalued?

Against its own history, PCRX is well below its usual price: the price is 56% below the $83.46 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is PCRX above its 200-week moving average?

Yes. PCRX is 33.5% above its 200-week average of $27.33. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Pacira BioSciences, Inc. growing?

Over the last five fiscal years Pacira BioSciences, Inc.'s revenue grew 11.1% a year and its earnings per share -45.5% a year; over ten years revenue grew 11.3% a year.

Cite this page

Funkfolio, “Pacira BioSciences, Inc. (PCRX) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/PCRX

Underlying data: Yahoo Finance; company filings with the SEC.